Genotype 2 Patients: What is the Optimum Therapy so Far?

Elisabetta Degasperi, Alessio Aghemo

Research output: Contribution to journalReview articlepeer-review


Since optimization studies with Peginterferon (PegIFN) and Ribavirin (Rbv), antiviral treatment of hepatitis C virus (HCV) genotype 2 patients consisted in a 24-week course of dual therapy, resulting in 80–85 % sustained virological response (SVR) rates. PegIFN/Rbv combination was effective in most patients; however, it was burdened by side effects and was suboptimal in difficult-to-treat subgroups, like advanced fibrosis stages. Despite the attempts of treatment individualization according to baseline and on-treatment predictors to increase efficacy and tolerability, many patients had no access to treatment due to comorbidities contraindicating PegIFN administration. In this scenario, the development of new drugs directly targeting HCV replication cycle opened the way to IFN-free combination regimens that could not only increase efficacy but also, most of all, reduce side effects and expand treatment access. This review is focused on new treatment options in HCV-2 patients, from phase III studies to real-life data.

Original languageEnglish
Pages (from-to)253-259
Number of pages7
JournalCurrent Hepatitis Reports
Issue number4
Publication statusPublished - Jan 1 2015


  • Antiviral therapy
  • Daclatasvir
  • Genotype 2
  • Hepatitis C
  • IFN-free regimens
  • Sofosbuvir

ASJC Scopus subject areas

  • Hepatology
  • Virology


Dive into the research topics of 'Genotype 2 Patients: What is the Optimum Therapy so Far?'. Together they form a unique fingerprint.

Cite this